Can Latin America's economies recover from the pandemic?
Few places have suffered as much from the Covid-19 pandemic as Latin America. A sustained commodity rally could help.

Few places have suffered as much from the Covid-19 pandemic as Latin America. Of the top five countries by total reported deaths globally, three – Brazil, Mexico and Peru – are in the region. Weak healthcare forced governments to implement very strict lockdowns last year, says The Economist. Tight budgets have constrained stimulus efforts. The result? GDP in Latin America and the Caribbean fell by 7% in 2020, compared with a global average contraction of 3%.
Latin America came into the crisis with “pre-existing conditions”, says Eric Parrado on Project Syndicate. Productivity has lagged more successful countries for decades. High commodity prices after the financial crisis gave Latin American governments an opportunity to turn things around. But they put reform “on the back burner” and raised spending on subsidies rather than infrastructure.
A bet on commodities
The region’s market is exceptionally cyclical: energy and materials stocks make up 34% of the MSCI EM Latin America index; financials comprise 23%. Information technology accounts for just 1.8%. Weak commodity prices have made this a miserable decade. The MSCI index has fallen by 40% over the last ten years in dollar terms. The recent commodities rally had given shares a boost, but that too has cooled, leaving the index up by just 2% so far this year. Brazil makes up two-thirds of the index, while Mexico accounts for just over a fifth. The remainder is largely made up of Chile, Peru and Colombia.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
On a price/earnings (p/e) ratio of 13.6, stocks are certainly cheap, but they don’t look so attractive given the risks, say James Norrington and Mary McDougall in the Investors’ Chronicle. The region’s politics have turned ugly; “horrifyingly, 91 politicians were killed, including 14 candidates”, in the months before Mexico’s legislative elections. Brazil’s election next year could see divisive president Jair Bolsonaro square off against former leader Lula da Silva, another polarising figure. “A Marxist-Leninist is poised to become Peru’s next president”, adds Ruchir Sharma in The Financial Times. A communist could also come to power in Chile. Still, history shows that the region’s economic fortunes depend on one thing: commodity prices. The economy boomed along with commodities in the 1970s and the 2000s. Bad decades for raw materials, such as the 2010s, are “often the harbinger of a better one to come”. A sustained commodity rally would negate worries about the latest crop of populists.
Not so fast, say Norrington and McDougall. Shares are cheap and could benefit from a cyclical boom, but “many of the attractive elements offered by Latin American economies… are also present in other emerging markets with less political risk.”
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
-
Reeves warned against property tax shake-up – 3 ways it could backfire on first-time buyers
Rachel Reeves reportedly has her eye on high-end property taxes in the upcoming Budget, but there are concerns a shake-up could unintentionally hamper those trying to get on the housing ladder
-
Average Brits want to retire five years before they can – who has the widest retirement gap?
Brits are expecting to work for longer than ever but there are big disparities in the number of extra working years predicted. A small tweak could help close the gap
-
Pierre-Édouard Stérin wants to make France great again
Conservative billionaire Pierre-Édouard Stérin is seeking to lead a political and spiritual renaissance across the Channel. The planning looks meticulous
-
Global investors have overlooked the top innovators in emerging markets
Opinion Carlos Hardenberg, portfolio manager, Mobius Investment Trust, highlights three emerging market stocks where he’d put his money
-
Pinewood Technologies: a drive for growth
Pinewood Technologies’ platform is one of the best in the business. Investors should buy in
-
'EV maker Faraday Future will crash'
Faraday Future Intelligent Electric is failing dismally to live up to its name, says Matthew Partridge
-
Investors should cheer the coming nuclear summer
The US and UK have agreed a groundbreaking deal on nuclear power, and the sector is seeing a surge in interest from around the world. Here's how you can profit
-
8 of the best houses for sale with follies
The best houses for sale with follies in the grounds – from a five-storey Victorian Gothic tower in Tonbridge, Kent, to a former mill in Oxfordshire with gardens that include a folly on an island in a lake
-
A tale of two Reits – why performance matters for valuation
AEW UK and Regional are two Reits that are valued very differently, despite a shared focus on properties outside London
-
Healthcare stocks look cheap, but tread carefully
Shares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?